This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klootwijk, W. Articles by de Greef, W. J. Search for Related Content PubMed PubMed Citation Articles by Klootwijk, W. Articles by de Greef, W. J.

Renal Clearance of the Thyrotropin-Releasing Hormone-Like Peptide Pyroglutamyl-Glutamyl-Prolineamide in Humans

Department of Internal Medicine and Clinical Endocrinology (W.K., R.D.H.d.B, W.W.d.H, T.J.V.) Department of Endocrinology and Reproduction (E.S.-L., C.A.J., R.A., W.J.d.G.), and Department of Urology (E.R.B.), Erasmus University, 3000 DR Rotterdam, The Netherlands

Address all correspondence and requests for reprints to: Dr. W. J. de Greef, Department of Endocrinology and Reproduction, Faculty of Medicine and Health Sciences, Erasmus University, 3000 DR Rotterdam, The Netherlands.

TRH-like peptides have been identified that differ from TRH (pGlu-His-ProNH₂) in the middle aminoacid. We have estimated TRH-like immunoreactivity (TRH-LI) in human serum and urine by RIA with TRH-specific antiserum 8880 or with antiserum 4319, which binds most peptides with the structure pGlu-X-ProNH₂. TRH was undetectable in serum (<25 pg/mL), but TRH-LI was detected with antiserum 4319 in serum of 27 normal subjects, 21 control patients, and 12 patients with carcinoid tumors (range 17–45, 5–79, and 18–16,600 pg/mL, respectively). Because serum was kept for at least 2 h at room temperature, which causes degradation of TRH, pGlu-Phe-ProNH₂, and pGlu-Tyr-ProNH₂, serum TRH-LI is not caused by these peptides. On high-performance liquid chromatography, serum TRH-LI coeluted with pGlu-Glu-ProNH₂ (<EEP-NH₂), a peptide produced in, among others, the prostate. Urine of normals and control patients also contained TRH-LI (range 1.14–4.97 and 0.24–5.51 ng/mL, respectively), with similar levels in males and females. TRH represented only 2% of urinary TRH-LI, and anion-exchange chromatography and high-performance liquid chromatography revealed that most TRH-LI in urine was <EEP-NH₂. In patients with carcinoid tumors, increased urinary TRH-LI levels were noted (range 1.35–962.4 ng/mL). Urinary TRH-LI correlated positively with urinary creatinine, and the urinary clearance rate of TRH-LI was similar to the glomerular filtration rate. In addition, serum TRH-LI was increased in 17 hemodialysis patients (43–373 pg/mL). This suggests that serum <EEP-NH₂ is cleared by glomerular filtration with little tubular resorption. The possible role of the prostate as a source of urinary TRH-LI was evaluated in 11 men with prostate cancer, showing a 25% decrease in urinary TRH-LI excretion after prostatectomy (0.19 ± 0.02 vs. 0.15 ± 0.01 ng/µmol creatinine, mean ± SEM). However, TRH-LI was similar in spontaneously voided urine and in urine obtained through a nephrostomy cannula from 16 patients with unilateral urinary tract obstruction (0.15 ± 0.01 vs. 0.14 ± 0.01 ng/µmol creatinine). These data indicate that: 1) TRH-LI in human serum represents largely <EEP-NH₂, which is cleared by renal excretion; 2) part of urinary <EEP-NH₂ is derived from prostatic secretion into the blood and not directly into urine; and 3) urinary <EEP-NH₂ can be used as marker for carcinoid tumors.

This article has been cited by other articles:

				A. J. Ruiz-Alcaraz and J. del Rio-Garcia Characterization of a Circulating N-Extended Form of the Thyrotropin-Releasing Hormone-Like Peptide pGlu-Glu-Pro Amide in Human Plasma J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6002 - 6007. [Abstract] [Full Text] [PDF]